Search

Your search keyword '"Guttman-Yassky, Emma"' showing total 244 results

Search Constraints

Start Over You searched for: Author "Guttman-Yassky, Emma" Remove constraint Author: "Guttman-Yassky, Emma" Topic dermatitis, atopic Remove constraint Topic: dermatitis, atopic
244 results on '"Guttman-Yassky, Emma"'

Search Results

1. Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood.

2. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.

3. Two-sample Mendelian randomization analysis identifies a causal association between atopic dermatitis and impetigo.

4. Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling.

5. Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies.

6. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.

7. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.

8. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.

9. Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations.

10. Mapping the immune cell landscape of severe atopic dermatitis by single-cell RNA-seq.

11. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond.

12. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

13. Proteomic alterations in patients with atopic dermatitis.

14. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.

15. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.

16. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).

17. Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.

18. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.

19. Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database.

21. Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines.

23. Diversity of atopic dermatitis and selection of immune targets.

25. CLA+ memory T cells in atopic dermatitis

26. Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies.

27. Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.

28. The role of Janus kinase signaling in the pathology of atopic dermatitis.

29. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.

31. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.

32. Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis.

33. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.

34. The impact of atopic dermatitis on alopecia areata: A 2-sample Mendelian randomization study.

35. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.

36. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.

37. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.

38. Age of onset defines two distinct profiles of atopic dermatitis in adults.

39. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry.

40. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.

41. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).

42. Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab.

44. Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis.

46. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

47. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.

48. Oral Janus kinase inhibitors for atopic dermatitis.

49. Comorbidities of atopic dermatitis-what does the evidence say?

50. No association between dupilumab use and short-term cancer development in atopic dermatitis patients.

Catalog

Books, media, physical & digital resources